Flagship Pioneering Completes $3.37 Billion Capital Pool

Flagship Pioneering

Flagship Pioneering, a Cambridge, Mass.-based bioplatform innovation company, announced an expansion of its capital base to support founding and growing its next generation of human health and sustainability companies.

Flagship re-opened Fund VII in April 2021 to current Limited Partners and a select group of new investors, raising an additional $2.23 billion for a total capital pool of $3.37 billion. This brings together its origination and growth strategies under one investment vehicle with a long-term focus on the creation, development, and growth of its first-in-category bioplatform companies.

Led by Noubar Afeyan, Ph.D., Founder and Chief Executive Officer, Stephen Berenson, Managing Partner, and Doug Cole, M.D., Managing Partner, Flagship Pioneering conceives, creates, resources, and develops first-in-category bioplatform companies to transform human health and sustainability.

The firm is actively building a division tasked with pioneering a new field that aims to protect, maintain, or improve people’s health before they get sick by proactively intervening in those who are seemingly healthy but at risk. It will encompass interventions that protect health from external threats (health security) as well as to prevent or delay the onset of disease (preemptive health) to better prepare for the next infectious disease threats, and to pursue bolder treatments for existing pandemic diseases such as obesity, cancer, and neurodegeneration.

Since its launch in 2000, the firm has originated and fostered more than 100 scientific ventures, resulting in over $90 billion in aggregate value. To date, Flagship has deployed over $2.4 billion in capital toward the founding and growth of its pioneering companies alongside more than $19 billion of follow-on investments from other institutions. The current Flagship ecosystem comprises 41 transformative companies, including Denali Therapeutics (NASDAQ: DNLI), Indigo Ag, Moderna (NASDAQ: MRNA), Rubius Therapeutics (NASDAQ: RUBY), Sana Biotechnology (NASDAQ: SANA), Seres Therapeutics (NASDAQ: MCRB), and Valo Health.